Androgen Receptor Blockade in Experimental Combination Therapy of Pancreatic Cancer

Srivani Konduri, Margaret Schwarz, Danielle Cafasso, Roderich E. Schwarz

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Reports on hormone receptor expression of pancreatic cancer (PaCa) cells and treatment responses to antihormonal therapy are still conflicting. Methods: Eight human PaCa cell lines were tested for androgen receptor (AR) protein levels by Western blot analysis. Cell proliferation in vitro was measured by sulforhodamine B analysis. AR agonists and inhibitors included dihydrotestosterone (DHT), testosterone (T), and flutamide (Flu). In vivo therapy of nude mouse xenografts tested Flu with gemcitabine (Gem) and/or bevacizumab (Bev). Results: Seven of eight human PaCa cell lines expressed detectable AR protein. Median relative expression compared with the AR positive control LnCaP was 21% (range: 16 to 63). Growth stimulation by DHT or T was minor (

Original languageEnglish (US)
Pages (from-to)378-386
Number of pages9
JournalJournal of Surgical Research
Volume142
Issue number2
DOIs
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

Investigational Therapies
Androgen Receptors
Pancreatic Neoplasms
Flutamide
Dihydrotestosterone
gemcitabine
lissamine rhodamine B
Cell Line
Heterografts
Nude Mice
Androgens
Testosterone
Proteins
Therapeutics
Western Blotting
Cell Proliferation
Hormones
Growth

Keywords

  • androgen receptor
  • combination therapy
  • hormonal therapy
  • pancreatic cancer

ASJC Scopus subject areas

  • Surgery

Cite this

Androgen Receptor Blockade in Experimental Combination Therapy of Pancreatic Cancer. / Konduri, Srivani; Schwarz, Margaret; Cafasso, Danielle; Schwarz, Roderich E.

In: Journal of Surgical Research, Vol. 142, No. 2, 10.2007, p. 378-386.

Research output: Contribution to journalArticle

Konduri, Srivani ; Schwarz, Margaret ; Cafasso, Danielle ; Schwarz, Roderich E. / Androgen Receptor Blockade in Experimental Combination Therapy of Pancreatic Cancer. In: Journal of Surgical Research. 2007 ; Vol. 142, No. 2. pp. 378-386.
@article{ea08a156805d481da3243e48c2a146bc,
title = "Androgen Receptor Blockade in Experimental Combination Therapy of Pancreatic Cancer",
abstract = "Background: Reports on hormone receptor expression of pancreatic cancer (PaCa) cells and treatment responses to antihormonal therapy are still conflicting. Methods: Eight human PaCa cell lines were tested for androgen receptor (AR) protein levels by Western blot analysis. Cell proliferation in vitro was measured by sulforhodamine B analysis. AR agonists and inhibitors included dihydrotestosterone (DHT), testosterone (T), and flutamide (Flu). In vivo therapy of nude mouse xenografts tested Flu with gemcitabine (Gem) and/or bevacizumab (Bev). Results: Seven of eight human PaCa cell lines expressed detectable AR protein. Median relative expression compared with the AR positive control LnCaP was 21{\%} (range: 16 to 63). Growth stimulation by DHT or T was minor (",
keywords = "androgen receptor, combination therapy, hormonal therapy, pancreatic cancer",
author = "Srivani Konduri and Margaret Schwarz and Danielle Cafasso and Schwarz, {Roderich E.}",
year = "2007",
month = "10",
doi = "10.1016/j.jss.2006.09.034",
language = "English (US)",
volume = "142",
pages = "378--386",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Androgen Receptor Blockade in Experimental Combination Therapy of Pancreatic Cancer

AU - Konduri, Srivani

AU - Schwarz, Margaret

AU - Cafasso, Danielle

AU - Schwarz, Roderich E.

PY - 2007/10

Y1 - 2007/10

N2 - Background: Reports on hormone receptor expression of pancreatic cancer (PaCa) cells and treatment responses to antihormonal therapy are still conflicting. Methods: Eight human PaCa cell lines were tested for androgen receptor (AR) protein levels by Western blot analysis. Cell proliferation in vitro was measured by sulforhodamine B analysis. AR agonists and inhibitors included dihydrotestosterone (DHT), testosterone (T), and flutamide (Flu). In vivo therapy of nude mouse xenografts tested Flu with gemcitabine (Gem) and/or bevacizumab (Bev). Results: Seven of eight human PaCa cell lines expressed detectable AR protein. Median relative expression compared with the AR positive control LnCaP was 21% (range: 16 to 63). Growth stimulation by DHT or T was minor (

AB - Background: Reports on hormone receptor expression of pancreatic cancer (PaCa) cells and treatment responses to antihormonal therapy are still conflicting. Methods: Eight human PaCa cell lines were tested for androgen receptor (AR) protein levels by Western blot analysis. Cell proliferation in vitro was measured by sulforhodamine B analysis. AR agonists and inhibitors included dihydrotestosterone (DHT), testosterone (T), and flutamide (Flu). In vivo therapy of nude mouse xenografts tested Flu with gemcitabine (Gem) and/or bevacizumab (Bev). Results: Seven of eight human PaCa cell lines expressed detectable AR protein. Median relative expression compared with the AR positive control LnCaP was 21% (range: 16 to 63). Growth stimulation by DHT or T was minor (

KW - androgen receptor

KW - combination therapy

KW - hormonal therapy

KW - pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=34548772350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548772350&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2006.09.034

DO - 10.1016/j.jss.2006.09.034

M3 - Article

C2 - 17559882

AN - SCOPUS:34548772350

VL - 142

SP - 378

EP - 386

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 2

ER -